Hashish (Cannabis Resin) and Blood Transfusion: Risks, Interactions, and Clinical Guidance

Hashish (hash) is a concentrated cannabis resin preparation with high Δ⁹-THC content (20–60% vs. 10–25% in flower). Its use around blood transfusion raises theoretical and practical concerns.

Pharmacological Effects Relevant to Transfusion

• Hemodynamic: THC → vasodilation, orthostatic hypotension, reflex tachycardia. May exacerbate transfusion-associated circulatory overload (TACO) or hypotension reactions.
• Immunomodulation: CB2 receptor activation suppresses cytokine release, neutrophil migration, NK cell activity — theoretical impact on transfusion-related immunomodulation (TRIM) and infection risk.
• Platelet function: Cannabis may inhibit platelet aggregation (ADP, collagen pathways) — potential additive bleeding risk with thrombocytopenia.
• Cognitive/psychomotor: Impaired coordination, sedation, anxiety/paranoia — complicates informed consent and post-transfusion monitoring.
• Drug interactions: CYP3A4/2C9 inhibition → affects metabolism of concomitant meds (e.g., tacrolimus, warfarin, opioids).

Direct Evidence on Transfusion Outcomes

None. No clinical studies examine hashish/cannabis use specifically in transfusion recipients. Guidelines extrapolate from general cannabis perioperative literature.

Current Recommendations

Pre-Transfusion

• Disclose use: Inform transfusion team (anesthesia, hematology, nursing).
• Abstain ≥24h (ideally 48–72h) before elective transfusion to reduce acute hemodynamic/cognitive effects.
• Chronic users: Do not abruptly stop (withdrawal: irritability, insomnia, nausea); coordinate with clinician.

During/Post-Transfusion

• Avoid use during transfusion and 24h after (monitoring window for reactions).
• Monitor vitals closely if recent use (orthostatic BP, mental status).
• Report any unusual symptoms (chest pain, dyspnea, severe headache) immediately.

Special Populations

• Sickle cell disease: Chronic pain patients often use cannabis; transfusions frequent. Multidisciplinary pain plan needed.
• Oncology: Antiemetic cannabis use common; coordinate with chemo/transfusion schedule.
• Pregnancy: Cannabis contraindicated; transfusion (e.g., for alloimmunization) requires abstinence.

Blood Donor Policies

• FDA/US: Deferral for "recreational drug use" varies by center; cannabis not explicitly listed but may fall under "intravenous drug use" if injected (hash is smoked/vaped).
• Canada/UK: No deferral for cannabis use alone; assess fitness to donate.
• Donor THC does not transmit psychoactive effects via blood components.

Open communication with the healthcare team ensures safe transfusion. Cannabis use is not an absolute contraindication, but timing and monitoring matter.